文献速递慢阻肺

COPD单次中度急性加重即可提示预后风险:12年死亡与未来加重分析

Prognostic Impact of Single Moderate Exacerbation in Patients With COPD: Analysis of 12-Year Mortality and Future Exacerbation Risk.
PubMed 文献 · Chest · 2026-07-29

基于韩国COPD亚组研究(KOCOSS)前瞻性多中心队列1551例患者,按首年急性加重史分组,评估第二年未来加重及最长12年全因与呼吸相关死亡。单次中度加重与未来中重度加重、重度加重、全因死亡及呼吸相关死亡风险升高独立相关;GOLD 2026加重史风险定义对10年全因死亡的区分度优于GOLD 2025。

要点

  • 单次中度加重者未来中重度加重风险升高(aIRR 2.42)。
  • 单次中度加重与呼吸相关死亡风险升高相关(aHR 3.21)。
  • GOLD 2026定义10年全因死亡区分度优于GOLD 2025(AUC 0.760 vs 0.734)。

核心结论

  • 单次中度急性加重可识别未来加重和死亡风险升高的COPD患者,支持GOLD 2026将其归为高风险。

研究设计与样本

  • 韩国COPD亚组研究(KOCOSS)前瞻性多中心队列,共分析1551例患者。
  • 按首年加重史分为无加重、1次中度加重、≥2次中度或≥1次重度加重。
  • 第二年未来加重用负二项回归评估,12年全因与呼吸相关死亡用Cox比例风险模型评估。
  • 以时间依赖AUC比较GOLD 2025与GOLD 2026加重史风险定义的预后表现。

主要发现

  • 241例(15.5%)发生1次中度加重,392例(25.3%)发生频繁或重度加重。
  • 1次中度加重与未来中重度加重风险升高相关(调整IRR 2.42;95%CI 1.85-3.17)。
  • 1次中度加重与未来重度加重风险升高相关(调整IRR 2.21;95%CI 1.27-3.85)。
  • 1次中度加重与全因死亡升高独立相关(调整HR 1.49;95%CI 1.02-2.15)。
  • 1次中度加重与呼吸相关死亡升高独立相关(调整HR 3.21;95%CI 1.76-5.88)。

关键数值与推荐

  • GOLD 2026将单次中度加重归为高风险(E组),本研究为其预后意义提供证据。
  • GOLD 2026定义10年全因死亡区分度:AUC 0.760,GOLD 2025为0.734,ΔAUC 0.025(95%CI 0.004-0.046)。

临床怎么用

  • 对COPD患者应详细询问首年加重史,单次中度加重即应视为高风险并加强随访管理。
  • 可按GOLD 2026加重史定义进行风险分层,关注未来加重与长期死亡风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2026 strategy lowered the threshold for defining high-risk COPD by classifying patients with a single moderate exacerbation as high risk (group E). Evidence supporting the prognostic significance of this change remains limited. RESEARCH QUESTION: Does 1 moderate exacerbation identify patients at increased risk of future exacerbations and long-term mortality, and does the GOLD 2026 exacerbation-based risk definition improve prognostic performance compared with GOLD 2025? STUDY DESIGN AND METHODS: We analyzed data from the Korean COPD Subgroup Study (KOCOSS), a prospective multicenter COPD cohort. Patients were classified by exacerbation history during the first year as no exacerbation, 1 moderate exacerbation, or ≥ 2 moderate or ≥ 1 severe exacerbations. Future exacerbations during the second year were evaluated using negative binomial regression. Twelve-year all-cause and respiratory mortality were assessed using Cox proportional hazards models. The prognostic performance of GOLD 2025 and GOLD 2026 exacerbation-based risk definitions was compared using time-dependent area under the curve analysis. RESULTS: Among 1,551 patients, 241 (15.5%) experienced 1 moderate exacerbation, and 392 (25.3%) experienced frequent or severe exacerbations. Compared with no exacerbations, 1 moderate exacerbation was associated with higher risks of future moderate-to-severe exacerbations (adjusted incidence rate ratio, 2.42; 95% CI, 1.85-3.17) and severe exacerbations (adjusted incidence rate ratio, 2.21; 95% CI, 1.27-3.85). Over long-term follow-up of up to 12 years, 1 moderate exacerbation was independently associated with increased all-cause mortality (adjusted hazard ratio, 1.49; 95% CI, 1.02-2.15) and respiratory mortality (adjusted hazard ratio, 3.21; 95% CI, 1.76-5.88). The GOLD 2026 definition showed better 10-year discrimination for all-cause mortality than the GOLD 2025 definition (area under the receiver operating characteristic curve, 0.760 vs 0.734; Δ area under the receiver operating characteristic curve, 0.025; 95% CI, 0.004-0.046). INTERPRETATION: Our results show that a single moderate exacerbation identifies patients at increased risk of future exacerbations and mortality, supporting their classification as high risk under GOLD 2026.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Choi JY, Yoon HK, Moon JY, et al. Prognostic Impact of Single Moderate Exacerbation in Patients With COPD: Analysis of 12-Year Mortality and Future Exacerbation Risk. Chest. 2026. PMID: 42526633. doi:10.1016/j.chest.2026.07.5219

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。